Адам ағзасындағы иммундық тежегіш CTLA-4 ақуызы

Mammalian protein found in humans

Cytotoxic T lymphocyte associated protein 4, (CTLA 4) also known as CD152 (cluster of differentiation 152), is a protein receptor that functions as an immune checkpoint and downregulates immune responses. CTLA 4 is constitutively expressed in regulatory T cells but only upregulated in conventional T cells after activation – a phenomenon which is particularly notable in cancers. It acts as an "off" switch when bound to CD80 or CD86 on the surface of antigen presenting cells. It is encoded by the gene CTLA4 in humans. The CTLA 4 protein is encoded by the Ctla 4 gene in mice.

CTLA 4 was first identified in 1991 as a second receptor for the T cell costimulation ligand B7. In November 1995, the labs of Tak Wah Mak and Arlene Sharpe independently published their findings on the discovery of the function of CTLA 4 as a negative regulator of T cell activation, by knocking out the gene in mice. Previous studies from several labs had used methods which could not definitively define the function of CTLA 4, and were contradictory.

CTLA 4 is a member of the immunoglobulin superfamily that is expressed by activated T cells and transmits an inhibitory signal to T cells. CTLA 4 is homologous to the T cell co stimulatory protein, CD28, and both molecules bind to CD80 and CD86, also called B7 1 and B7 2 respectively, on antigen presenting cells. CTLA 4 binds CD80 and CD86 with greater affinity and avidity than CD28 thus enabling it to outcompete CD28 for its ligands. CTLA 4 transmits an inhibitory signal to T cells, CTLA 4 is also found in regulatory T cells (Tregs) and contributes to their inhibitory function. T cell activation through the T cell receptor and CD28 leads to increased expression of CTLA 4. The mechanism by which CTLA 4 acts in T cells remains somewhat controversial. Biochemical evidence suggested that CTLA 4 recruits a phosphatase to the T cell receptor (TCR), thus attenuating the signal. This work remains unconfirmed in the literature since its first publication. More recent work has suggested that CTLA 4 may function in vivo by capturing and removing CD80 and CD86 from the membranes of antigen presenting cells, thus making these unavailable for triggering of CD28. In addition to that, it has been found that dendritic cell (DC) Treg interaction causes sequestration of Fascin 1, an actin bundling protein essential for immunological synapse formation and skews Fascin 1–dependent actin polarization in antigen presenting DCs toward the Treg cell adhesion zone. Although it is reversible upon T regulatory cell disengagement, this sequestration of essential cytoskeletal components causes a lethargic state of DCs, leading to reduced T cell priming. This suggests Treg mediated immune suppression is a multi step process. In addition to CTLA 4 CD80/CD86 interaction, fascin dependent polarization of the cytoskeleton towards DC Treg immune synapse may play a pivotal role. CTLA 4 may also function via modulation of cell motility and/or signaling through PI3 kinase Early multiphoton microscopy studies observing T cell motility in intact lymph nodes appeared to give evidence for the so called ‘reverse stop signaling model’. In this model CTLA 4 reverses the TCR induced ‘stop signal’ needed for firm contact between T cells and antigen presenting cells (APCs). However, those studies compared CTLA 4 positive cells, which are predominantly regulatory cells and are at least partially activated, with CTLA 4 negative naive T cells. The disparity of these cells in multiple regards may explain some of these results. Other groups who have analyzed the effect of antibodies to CTLA 4 in vivo have concluded little or no effect upon motility in the context of anergic T cells. Antibodies to CTLA 4 may exert additional effects when used in vivo, by binding and thereby depleting regulatory T cells.

The protein contains an extracellular V domain, a transmembrane domain, and a cytoplasmic tail. Alternate splice variants, encoding different isoforms, have been characterized. The membrane bound isoform functions as a homodimer interconnected by a disulfide bond, while the soluble isoform functions as a monomer. The intracellular domain is similar to that of CD28, in that it has no intrinsic catalytic activity and contains one YVKM motif able to bind PI3K, PP2A and SHP 2 and one proline rich motif able to bind SH3 containing proteins. The first role of CTLA 4 in inhibiting T cell responses seem to be directly via SHP 2 and PP2A dephosphorylation of TCR proximal signalling proteins such as CD3 and LAT. CTLA 4 can also affect signalling indirectly via competing with CD28 for CD80/86 binding. CTLA 4 can also bind PI3K, although the importance and results of this interaction are uncertain.

Variants in this gene have been associated with Type 1 diabetes, Graves' disease, Hashimoto's thyroiditis, celiac disease, systemic lupus erythematosus, thyroid associated orbitopathy, primary biliary cirrhosis and other autoimmune diseases. Polymorphisms of the CTLA 4 gene are associated with autoimmune diseases such as rheumatoid arthritis, autoimmune thyroid disease and multiple sclerosis, though this association is often weak. In systemic lupus erythematosus (SLE), the splice variant sCTLA 4 is found to be aberrantly produced and found in the serum of patients with active SLE.

Germline haploinsufficiency of CTLA 4 leads to CTLA 4 deficiency or CHAI disease (CTLA4 haploinsufficiency with autoimmune infiltration), a rare genetic disorder of the immune system. This may cause a dysregulation of the immune system and may result in lymphoproliferation, autoimmunity, hypogammaglobulinemia, recurrent infections, and may slightly increase one’s risk of lymphoma. CTLA 4 mutations have first been described by a collaboration between the groups of Dr. Gulbu Uzel, Dr. Steven Holland, and Dr. Michael Lenardo from the National Institute of Allergy and Infectious Disease, Dr. Thomas Fleisher from the NIH Clinical Center at the National Institutes of Health, and their collaborators in 2014. In the same year a collaboration between the groups of Dr. Bodo Grimbacher, Dr. Shimon Sakaguchi, Dr. Lucy Walker and Dr. David Sansom and their collaborators described a similar phenotype. CTLA 4 mutations are inherited in an autosomal dominant manner. This means a person only needs one abnormal gene from one parent. The one normal copy is not enough to compensate for the one abnormal copy. Dominant inheritance means most families with CTLA 4 mutations have affected relatives in each generation on the side of the family with the mutation.

Symptomatic patients with CTLA 4 mutations are characterized by an immune dysregulation syndrome including extensive T cell infiltration in a number of organs, including the gut, lungs, bone marrow, central nervous system. and kidneys. Most patients have diarrhea or enteropathy. Lymphadenopathy and hepatosplenomegaly are also common, as is autoimmunity. The organs affected by autoimmunity vary but include thrombocytopenia, hemolytic anemia, thyroiditis, type I diabetes, psoriasis, and arthritis. Respiratory infections are also common. Importantly, the clinical presentations and disease courses are variable with some individuals severely affected, whereas others show little manifestation of disease. This “variable expressivity,” even within the same family, can be striking and may be explained by differences in lifestyle, exposure to pathogens, treatment efficacy, or other genetic modifiers. This condition is described to have incomplete penetrance of disease. Penetrance is said to be incomplete when some individuals fail to express the trait and seem completely asymptomatic, even though they carry the allele. The penetrance is estimated to be about 60%. The clinical symptoms are caused by abnormalities of the immune system. Most patients develop reduced levels of at least one immunoglobulin isotype, and have low CTLA 4 protein expression in T regulatory cells, hyperactivation of effector T cells, low switched memory B cells, and progressive loss of circulating B cells. The fusion protein CTLA4 Ig is commercially available as Orencia (abatacept). A second generation form of CTLA4 Ig known as belatacept was recently approved by the FDA based on favorable results from the randomized Phase III BENEFIT (Belatacept Evaluation of Nephroprotection and Efficacy as First Line Immunosuppression Trial) study. It was approved for renal transplantation in patients that are sensitized to Epstein–Barr virus (EBV).

Conversely, there is increasing interest in the possible therapeutic benefits of blocking CTLA 4 (using antagonistic antibodies against CTLA such as ipilimumab—FDA approved for melanoma in 2011—as a means of inhibiting immune system tolerance to tumours and thereby providing a potentially useful immunotherapy strategy for patients with cancer). Another is tremelimumab.